http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
BTG Announces National Reimbursement for TheraSphere® in France
-
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
-
BTG Announces Global Launch of the ICEfx™ Cryoablation System
-
SpotX Releases New 'Global TV and Video Trends' White Paper
-
Dentsu's CCI to Bring SpotX Video Ad Serving Platform to Domestic Broadcasting Stations in Japan
-
SpotX Launches Live CTV Educational Series for Advertisers
-
SpotX and Sharethrough Announce New Integration, Bringing Together Premium Outstream and Native Video Supply At Unprecedented Scale
-
SpotX Launches Online Resource Library For Publishers Seeking GDPR Guidance
-
SpotX To Host Go Live, Exclusive Two-City Event To Explore Live OTT Advertising
-
SpotX Expands Partnership with zvelo to Ensure Brand Safety by Filtering Out Fake News Content and Other Escalating Brand-Objectionable Categories
-
SpotX Provides Total Campaign Audience Insights for Connected TV
-
SpotX and ZypMedia Capture Local Advertiser Budgets for OTT
-
SpotX Doubles Down on Digital Video Advertising Safety, Granted Renewal on All Trustworthy Accountability Group (TAG) Certifications
-
Pluto TV Teams Up With SpotX To Drive Advertising Demand and Monetization of Premium Video
-
Vewd selects SpotX as their programmatic video partner
-
SpotX Infographic Reveals Growth of Connected TV Advertising in Europe
-
Scale matters: SpotX and smartclip form the new global ad tech powerhouse
-
SpotX Releases Detailed Insights About Current State of Video Advertising on OTT
-
fuboTV Taps SpotX For Programmatic Monetization of OTT Content to Further Drive Business Growth
-
SpotX announces interoperability with Amazon Web Services to monetize delivery of premium video content to consumers
-
SpotX Reports 18X Increase in Global Over-The-Top Video Ad Spend in 2017
-
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC
-
First Patient Treated With Microscopic Beads Pre-loaded With a Targeted Cancer Drug and Visible on CT Scans

